Evidence map›Paper›PMID 40727208›Full record

ArticleIndian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India2025

Comparative Mortality and Risk Analysis in Mucormycosis Cases: Pre-Pandemic Versus COVID-19 Association.

Masoud Janipour, Alireza Shahriari, Ali Faramarzi, Seyed Hossein Owji, Mohammad Ehsan Golshannia, Maryam Kherad, Maryam Rahimi, Vahid Hajianpour, Behzad Khademi, Amirhossein Babaei

Abstract read
In one paragraph

Article in Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masoud JanipourOtolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.
Alireza ShahriariOtolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali FaramarziOtolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0003-4814-1729
Seyed Hossein OwjiOtolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Ehsan GolshanniaOtolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.
Maryam KheradOtolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.
Maryam RahimiOtolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.
Vahid HajianpourStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Behzad KhademiPoostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0002-9316-309X
Amirhossein BabaeiOtolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0003-0251-1712

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aims to compare the clinical profiles, outcomes, and mortality-related risk factors of COVID-19-associated mucormycosis (CAM) with cases identified before the pandemic. Additionally, it seeks to evaluate the impact of the COVID-19 pandemic on the epidemiology and severity of mucormycosis infections. Study Design: Retrospective, observational study. Setting: The study was conducted across multiple medical centers in Shiraz, Iran. Methods: We reviewed clinical data of patients diagnosed with mucormycosis before and during the COVID-19 pandemic. The study included a detailed analysis of demographic profiles, clinical characteristics, risk factors, treatment outcomes, and mortality. Mortality-related risk factors were specifically analyzed through logistic regression models to identify predictors of poor outcomes in CAM patients. Results: The study included 122 cases of mucormycosis, with 85 cases associated with COVID-19. Patients with CAM showed higher prevalences of diabetes mellitus and hypertension compared to pre-pandemic cases, while malignancies were higher in peri-pandemic cases than in CAM cases ( Conclusion: COVID-19 has markedly affected the severity and mortality of mucormycosis, with CAM cases showing worse outcomes than pre-pandemic incidences. Our study emphasizes the need for aggressive management and increased awareness of risk factors to enhance survival rates in CAM patients during the pandemic.

Indexed as

COVID-19Diabetes MellitusMortalityMucormycosisRisk Factors

Identifiers

PMID40727208
PMCPMC12297118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.